Sharon Mates, Chairman, President & CEO at Intra-Cellular Therapies, Inc. (ITCI), sold 100,000 shares at $25.99 ($2.6M) on 2020-11-10, disclosed to the SEC on 2020-11-12.
Open-market sale of $2.6M ITCI by Chairman, President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.99 | 30,869 | $802K | 30.5% |
| 2 | $25.99 | 30,869 | $802K | 30.5% |
| 3 | $26.91 | 19,131 | $515K | 19.5% |
| 4 | $26.91 | 19,131 | $515K | 19.5% |
| Total | $26.34 avg | 100,000 | $2.6M | 100% |
| Filing → |
| ITCI | SELL | 2024-08-28 | $14.1M | — | Filing → |
| ITCI | SELL | 2024-08-23 | $18.0M | — | Filing → |
| ITCI | SELL | 2024-03-11 | $8.1M | — | Filing → |